A Randomized, Double-blind, Parallel Group, Active-controlled Study to Compare the Systolic Blood Pressure Lowering Efficacy of Aliskiren, Ramipril and a Combination of Aliskiren and Amlodipine, With an Initial 8-week Evaluation, Followed by a 2-3 Year Follow-up to Compare Long-term Safety of an Aliskiren-based Regimen to a Ramipril-based Regimen in Hypertensive Patients ≥ 65 Years of Age

Trial Profile

A Randomized, Double-blind, Parallel Group, Active-controlled Study to Compare the Systolic Blood Pressure Lowering Efficacy of Aliskiren, Ramipril and a Combination of Aliskiren and Amlodipine, With an Initial 8-week Evaluation, Followed by a 2-3 Year Follow-up to Compare Long-term Safety of an Aliskiren-based Regimen to a Ramipril-based Regimen in Hypertensive Patients ≥ 65 Years of Age

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Oct 2015

At a glance

  • Drugs Aliskiren (Primary) ; Amlodipine; Hydrochlorothiazide; Ramipril
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms ASSESS
  • Sponsors Novartis
  • Most Recent Events

    • 07 Apr 2015 Planned End Date changed from 1 Apr 2018 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 07 Apr 2015 Planned primary completion date changed from 1 Apr 2018 to 1 Jun 2018 as per ClinicalTrials.gov record.
    • 07 Apr 2015 Planned initiation date changed from 1 Apr 2015 to 1 May 2015 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top